Related Experiment Video
Updated: Jul 7, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Commentary on oncolytic viruses: past, present, and future
Christopher Larson1, Bryan Oronsky2, Tony R Reid1
1EpicentRx Inc, La Jolla, California, USA.
Abstract:
Whither oncolytic viruses? From the peak of their popularity in the early 2000s, when the ONYX-015 adenovirus had just entered the clinic, and then again in 2015 when the Food and Drug Administration-approved talimogene laherparepvec (also known as OncoVEXGM-CSF), which briefly revived interest, oncolytic viruses (OVs) have mostly fallen out of favor despite the many pharmaceutical companies with OVs in development.This commentary enumerates and addresses the core conceptions, perceptions, and misconceptions that characterize the current 'trough of disillusionment' in which the field of anticancer virotherapy finds itself and suggests reasons for optimism.
Insights
Oncolytic viruses (OVs) show promise for cancer treatment but have faced declining interest. This commentary addresses misconceptions and offers reasons for renewed optimism in anticancer virotherapy.
Area of Science:
- Oncology
- Virology
- Biotechnology
Background:
- Oncolytic viruses (OVs) experienced peak popularity in the early 2000s and a resurgence in 2015 with FDA approval of talimogene laherparepvec.
- Despite pharmaceutical development, OVs have largely fallen out of favor, entering a 'trough of disillusionment'.
Purpose of the Study:
- To enumerate and address misconceptions surrounding oncolytic virus therapy.
- To provide a balanced perspective on the current state of anticancer virotherapy.
- To identify reasons for optimism in the field of OVs.
Main Methods:
- This is a commentary, not an experimental study.
- Analysis of historical trends and perceptions in oncolytic virus research.
- Discussion of current challenges and future directions in anticancer virotherapy.
Main Results:
- The field of oncolytic virotherapy is characterized by specific conceptions, perceptions, and misconceptions.
- Several factors contribute to the current 'trough of disillusionment' for OVs.
- Despite challenges, there are grounds for optimism regarding the future of OV-based cancer treatments.
Conclusions:
- Addressing misconceptions is crucial for advancing oncolytic virus therapy.
- Renewed interest and development in OVs are warranted.
- Anticancer virotherapy holds significant potential for future cancer treatment strategies.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mechanisms of Retrovirus-induced Cancers
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

